Meningococcal (Groups A, C, Y, W) Conjugate Vaccine (MenQuadfi) Report issue

Vaccine Approved FDA
AACT MeSH

Active Ingredient History

NOW
  • Now
Meningococcal vaccine refers to any vaccine used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

4cmenb vaccine | acwyvax | bexsero | conjugated meningococcal acwy-tt | group c meningococcal polysaccharide-tetansu toxoid conjugate | gsk3536820a | mcv-acyw135 vaccine | menabcwy | menactra | menacwy | menacwy conjugate vaccine | menacwy-crm | menacwy-crm197 | menacwy-ps | menacwy vaccine | men-acyw135 | mencevax | menc-tt | meningococcal group a, c, w-135 and y conjugate vaccine | meningococcal polysaccharide diphtheria toxoid conj. | meningococcal polysaccharide (serogroups a, c, y and w-135) diphtheria toxoid conjugate vaccine | meningococcal polysaccharide tetanus protein conjugate | neisseria meningitidis serogroup a polysaccharide conjugated to tetanus toxoid / neisseria meningitidis serogroup c polysaccharide conjugated to tetanus toxoid /neisseria meningitidis serogroup w-135 polysaccharide conjugated to tetanus toxoid / neisseria meningitidis serogroup y polysaccharide conjugated to tetanus toxoid | nimenrix

Organizations (50)

Research & Development (50)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (43)

Approved Indications (1)


 

Meningococcal Vaccines (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (43)


 

Bacterial Infections (Phase 3)

Chickenpox (Phase 3)

Coronavirus (Phase 3)

Diarrhea (Phase 1/Phase 2)

Diphtheria (Phase 4)

Diphtheria-Tetanus-Pertussis Vaccine (Phase 3)

Dysentery, Bacillary (Phase 1/Phase 2)

Encephalitis, Japanese (Phase 3)

Gonorrhea (Phase 3)

Haemophilus influenzae (Phase 4)

Haemophilus influenzae type b (Phase 3)

Healthy Volunteers (Phase 3)

Hemorrhagic Fever, Ebola (Phase 2)

Hepatitis B (Phase 3)

HIV (Phase 4)

HIV Infections (Phase 4)

Immunization (Phase 4)

Influenza, Human (Phase 4)

Malaria (Phase 2)

Measles (Phase 3)

Meninges (Phase 3)

Meningitis (Phase 4)

Meningitis, Meningococcal (Phase 4)

Meningococcal Infections (Phase 4)

Meningococcal Vaccines (Phase 3)

Multiple Sclerosis (Phase 2)

Mumps (Phase 3)

Neisseria meningitidis (Phase 3)

Neoplasms, Glandular and Epithelial (Phase 3)

Papillomavirus Infections (Phase 3)

Pertussis Vaccine (Phase 4)

Pneumococcal Infections (Phase 3)

Rabies (Phase 3)

Respiratory Syncytial Viruses (Phase 1/Phase 2)

Respiratory Syncytial Virus Infections (Phase 1)

Respiratory Tract Infections (Phase 1)

Rubella (Phase 3)

Sepsis (Phase 4)

Tetanus (Phase 4)

Typhoid Fever (Phase 3)

Virus Diseases (Phase 3)

Whooping Cough (Phase 4)

Yellow Fever (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 183
  • # of Trial Organizations: 50

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue